Skip to content

Advertisement

  • Meeting abstract
  • Open Access

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

  • 1, 3,
  • 4,
  • 3,
  • 2,
  • 2,
  • 4,
  • 5 and
  • 3
Breast Cancer Research20002 (Suppl 1) :P3.07

https://doi.org/10.1186/bcr158

  • Published:

Keywords

  • Breast Cancer
  • Breast Carcinoma
  • Gene Amplification
  • Human Breast Carcinoma
  • TP53 Status

Full text

Activation of the HER-2 proto-oncogene and inactivation of the TP53 tumour-suppressor gene belong to the most common genetic changes in human breast carcinomas. Both appear to be of prognostic significance, at least in patients with node-positive disease. The relevance of these changes in node-negative disease, however, still remains uncertain. Moreover, the relationship between HER-2 and TP53 status remains to be fully clarified.

HER-2 and TP53 status were determined in 261 breast carcinomas collected from Norwegian breast cancer patients diagnosed between 1984 and 1994. HER-2 status was determined using immunohistochemistry. A subset of the tumours was also examined with regard to gene amplification using the Southern blot technique. A significant association was found between the presence of gene amplification and positive HER-2 immunostaining in the tumour. The tumours were also examined for TP53 alterations using CDGE (constant denaturant gel electrophoresis) and immunohistochemistry. A significant association was found between the presence of HER-2 activation and TP53 inactivation in the tumour. Survival analyses will be presented.

Authors’ Affiliations

(1)
Departments of Oncology, Norway
(2)
Surgery, Ullevål University Hospital, N-0407 Oslo, Norway
(3)
Departments of Genetics, Norway
(4)
Oncology, Norway
(5)
Pathology, The Norwegian Radium Hospital, N-0310 Oslo, Norway

Copyright

Advertisement